Comparative Pharmacology
Head-to-head clinical analysis: METRETON versus METROGEL VAGINAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRETON versus METROGEL VAGINAL.
METRETON vs METROGEL-VAGINAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.
None Documented
None Documented
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
Terminal elimination half-life: 6-8 hours (prolonged in hepatic impairment; half-life may exceed 20 hours in severe hepatic disease)
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Renal: 60-80% unchanged; fecal/biliary: 6-15%
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)